Trials / Completed
CompletedNCT02398513
Regorafenib Phase I Study in Mainland Chinese Patients
Uncontrolled, Open-label, Non-randomized, Phase I Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Regorafenib in Chinese Patients (China Mainland) With Advanced, Refractory Solid Tumors)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to define the pharmacokinetic of Regorafenib administered orally as a single agent in Chinese patients with advance solid tumors. The second objective include the evaluation of safety, tolerability, and efficacy of Chinese patents treated with Regorafenib
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Regorafenib (Stivarga, BAY73-4506) | Regorafenib 160 mg per oral |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2015-11-01
- Completion
- 2016-06-01
- First posted
- 2015-03-25
- Last updated
- 2016-08-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02398513. Inclusion in this directory is not an endorsement.